Pulmonary hypertension (PH) associated with chronic lung disease (CLD) is both common
and underrecognised. The presence of PH in the setting of lung disease has been …

Pulmonary hypertension (PH) because of chronic lung disease is categorized as Group 3
PH in the most recent classification system. Prevalence of these diseases is increasing over …

Pulmonary hypertension (PH) developing secondarily in pulmonary fibrosis (PF) patients
(PF-PH) is a frequent co-morbidity. The high prevalence of PH in PF patients is very …

Pulmonary hypertension (PH) due to interstitial lung disease (ILD; PH-ILD) can complicate a
multitude of ILDs, including idiopathic pulmonary fibrosis, chronic hypersensitivity …

The past 20 years have seen major advances in the diagnosis and management of
pulmonary hypertension, a disease associated with significant morbidity and mortality. The …

Pulmonary hypertension (PH) is a frequent and important complication of chronic obstructive
pulmonary disease (COPD). It is associated with worse clinical courses with more frequent …

Pulmonary hypertension (PH) complicates the treatment of interstitial lung disease (ILD)
patients resulting in poor functional status and worse outcomes. Early recognition of PH in …

Pulmonary parenchymal and vascular damage are frequently reported in COVID-19 patients
and can be assessed with unenhanced chest computed tomography (CT), widely used as a …

Pulmonary hypertension is a debilitating condition that frequently develops in the setting of
interstitial lung disease, likely related to chronic alveolar hypoxemia and pulmonary vascular …

Pulmonary hypertension related to chronic lung disease, mainly represented by COPD and
idiopathic pulmonary fibrosis, is associated with a worse outcome when compared with …